At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years
- ✓Confirmed recurrent or metastatic NSCLC without curative options
- ✓Measurable disease by RECIST 1.1
- ✓Prior standard of care chemotherapy and immunotherapy required
- ✕Active autoimmune disease requiring systemic treatment in past 12 months
- ✕Immunodeficiency or receiving systemic steroids >10 mg prednisone equivalent within 7 days before treatment
- ✕Known active chronic infections (HIV/AIDS, active Hepatitis B or C)
- ✕Cirrhosis (Child-Pugh B or worse) or cirrhosis with hepatic encephalopathy or clinically meaningful ascites
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib Trial of PBF-1129 and Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
In Brief
A Phase 1 clinical trial evaluating Adenosine A2B Receptor Antagonist PBF-1129, Biospecimen Collection, and 1 other intervention for Metastatic Lung Non-Small Cell Carcinoma and 4 related conditions. Currently recruiting, targeting 30 participants across 1 site.
Detailed Summary
This phase I trial studies the side effects and best dose of PBF-1129 in combination with nivolumab in treating patients with non-small cell lung cancer that has come back (recurrent) or spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as PBF-1129 and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Study Details
Timeline
Interventions
Given PO
Correlative studies
Given IV